The findings obtained from gene expression and plasma protein level analyses suggest that higher expression of VEGFB and TGFB1, higher plasma levels of VEGF-C, and lower plasma levels of VEGF-A are distinguishing characteristics of patients with LEAD, differentiating them from those with AAA and VV. Here, VEGFB is linked to triple-A syndrome.